Sanara MedTech (SMTI) AI Stock Analysis

• Market Cap: $270.19M
• Dividend Yield: N/A
• Average Volume (3M): 24.04K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.08
• Revenue Growth: 34.29%
• EPS Growth: -49.21%
• Country: US
• Employees: 141
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.23
• Shares Outstanding: 8,902,351
• 10 Day Avg. Volume: 25,392
• 30 Day Avg. Volume: 24,041
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.01
• Enterprise Value/Revenue: 2.81
• Enterprise Value/Gross Profit: 3.10
• Enterprise Value/Ebitda: 194.79
• 1Y Price Target: $50.00
• Price Target Upside: 69.38% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 51 Neutral
• Price Target: $31.00 ▲(5.01% Upside)

Sanara MedTech's overall stock score is driven by strong revenue growth and profitability improvements in its Surgical segment, as highlighted in the earnings call. However, significant challenges remain, including profitability and cash flow issues, a negative P/E ratio, and bearish technical indicators. The company's reliance on debt and ongoing losses in the THP segment further weigh on the score.

Positive Factors

Revenue Growth

The strong revenue growth in the Surgical segment indicates effective market penetration and product demand, supporting long-term business expansion.

Profitability Improvements

Profitability improvements in the Surgical segment reflect operational efficiency and cost management, enhancing financial stability.

Market Expansion

The expansion of the customer base and distributor network strengthens market presence and supports sustainable revenue growth.

Negative Factors

Profitability Challenges

Negative net profit margin indicates ongoing operational inefficiencies, which could hinder long-term financial health and growth potential.

Cash Flow Issues

Negative free cash flow growth suggests liquidity issues, potentially limiting the company's ability to invest in growth opportunities.

Debt Reliance

Increased reliance on debt can strain financial flexibility and increase risk, impacting long-term sustainability if not managed carefully.

Sanara MedTech Business Overview & Revenue Model

Company Description

Sanara MedTech Inc. (SMTI) is a medical technology company focused on developing and commercializing advanced wound care products and regenerative medicine solutions. The company operates primarily in the healthcare sector, providing innovative treatment options that enhance healing processes for patients suffering from chronic wounds and other medical conditions. Sanara's core products include bioengineered wound care solutions and various medical devices that promote tissue regeneration and healing.

How the Company Makes Money

Sanara MedTech generates revenue through the sale of its proprietary wound care and regenerative medicine products, which are marketed to hospitals, clinics, and healthcare providers. The company utilizes a direct sales force and distribution partnerships to reach its target markets effectively. Key revenue streams include product sales, licensing agreements, and potentially reimbursement from insurance providers for its medical solutions. Strategic partnerships with healthcare institutions and organizations also enhance its market presence and contribute to its earnings, as they may involve collaborative research, co-marketing arrangements, or joint ventures that expand the company's product offerings and market access.

Sanara MedTech Financial Statement Overview

Summary

Sanara MedTech shows strong revenue growth and a high gross profit margin, but faces challenges with profitability, cash flow, and increased debt reliance. These financial risks need addressing for long-term stability.

Income Statement

Sanara MedTech has shown a positive revenue growth rate of 6.19% in the TTM, indicating a healthy expansion in sales. The gross profit margin is strong at 91.76%, reflecting efficient cost management. However, the company is facing profitability challenges with a negative net profit margin of -10.22% and negative EBIT margin, indicating operational inefficiencies.

Balance Sheet

The company's debt-to-equity ratio has increased to 1.28 in the TTM, suggesting a higher reliance on debt financing, which could pose a risk if not managed carefully. The return on equity is negative, indicating that the company is not generating profits from shareholders' equity. The equity ratio is moderate, showing a balanced asset financing structure.

Cash Flow

The free cash flow growth rate is significantly negative at -102.55%, indicating cash flow challenges. The operating cash flow to net income ratio is low at 0.25, suggesting limited cash generation from operations relative to net income. The free cash flow to net income ratio is also low, pointing to potential liquidity issues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	97.24M	86.67M	64.99M	45.84M	24.14M	15.59M
Gross Profit	88.11M	78.53M	57.14M	39.48M	21.83M	13.97M
EBITDA	1.40M	-1.86M	-289.10K	-9.67M	-7.22M	-4.02M
Net Income	-9.94M	-9.66M	-4.30M	-7.94M	-7.92M	-4.36M
Balance Sheet
Total Assets	98.77M	88.09M	73.87M	61.04M	36.40M	9.83M
Cash, Cash Equivalents and Short-Term Investments	16.96M	15.88M	5.15M	8.96M	18.65M	455.37K
Total Debt	45.45M	32.29M	11.79M	819.22K	425.44K	481.38K
Total Liabilities	63.38M	49.18M	29.28M	19.32M	6.24M	3.99M
Stockholders Equity	35.40M	39.40M	44.83M	41.83M	30.64M	6.15M
Cash Flow
Free Cash Flow	58.91K	-229.63K	-3.51M	-6.30M	-5.56M	-5.68M
Operating Cash Flow	3.65M	-23.78K	-3.25M	-5.55M	-4.81M	-4.03M
Investing Cash Flow	-15.59M	-6.61M	-10.21M	-3.51M	-5.28M	-2.74M
Financing Cash Flow	22.76M	17.37M	9.64M	-627.35K	28.30M	622.33K

Sanara MedTech Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 29.52
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SMTI, the sentiment is Negative. The current price of 29.52 is below the 20-day moving average (MA) of 30.38, below the 50-day MA of 32.17, and below the 200-day MA of 31.19, indicating a bearish trend. The MACD of -0.44 indicates Negative momentum. The RSI at 47.81 is Neutral, neither overbought nor oversold. The STOCH value of 72.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SMTI.

Sanara MedTech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INFU	―	$213.45M	44.06	9.39%	―	8.13%	1293.06%
STXS	―	$270.48M	―	-198.62%	―	33.94%	-6.91%
UTMD	―	$187.63M	16.56	9.59%	2.06%	-12.35%	―
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SMTI	―	$270.19M	―	-25.78%	―	34.29%	-49.21%
OSUR	―	$209.90M	-4.20	-12.65%	―	-49.35%	-285.61%

Sanara MedTech Corporate Events

Sanara MedTech Appoints New CEO Ahead of Growth

On August 29, 2025, Sanara MedTech‘s Board of Directors appointed Seth D. Yon as the new President and Chief Executive Officer, effective September 15, 2025, succeeding Ronald T. Nixon, who will continue as Executive Chairman. This leadership transition is part of a strategic initiative to position Sanara for future growth, with Mr. Yon bringing extensive experience from his previous roles within the company, contributing to its significant revenue growth. Additionally, Ashley Mackey was designated as the principal accounting officer, succeeding Elizabeth B. Taylor, who remains the Chief Financial Officer.

The most recent analyst rating on (SMTI) stock is a Hold with a $33.00 price target. To see the full list of analyst forecasts on Sanara MedTech stock, see the SMTI Stock Forecast page.

Sanara MedTech’s Earnings Call: Growth Amid Challenges

Sanara MedTech’s recent earnings call painted a picture of robust growth and strategic challenges. The company reported significant revenue growth and profitability improvements in its Surgical segment, driven by strong product sales and enhanced operational efficiency. However, this positive momentum is somewhat tempered by ongoing losses in the THP segment, which necessitates a strategic reevaluation to balance the overall performance.

Sanara MedTech Reports Strong Revenue Growth in Q2 2025

Sanara MedTech Inc. is a medical technology company that develops and commercializes innovative products aimed at improving clinical outcomes and reducing healthcare costs in the surgical, chronic wound, and skin markets. The company operates primarily in North America, focusing on advanced wound care and surgical tissue repair markets.